Overview

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Status:
RECRUITING
Trial end date:
2026-08-18
Target enrollment:
Participant gender:
Summary
Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Shandong Cancer Hospital and Institute
Treatments:
Radiation
sintilimab